Press Release: BioElectronics Corporation to Present at the NobleCon Online Pain Management Investor Forum on Channelchek.com

BioElectronics Corporation to Present at the NobleCon Online Pain Management Investor Forum on Channelchek.com Frederick, MD, Oct. 07, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — BioElectronics Corporation (OTC: BIEL), a leader in the development and manufacturing of non-invasive electroceuticals, today announced that Sree Koneru, Ph.D., will present at the Pain Management Investor Forum to be … Continue Reading

BioElectronics Corporation Discusses Q2 Financials

Revenue Growth Exceeds 665% FREDERICK, MARYLAND, Aug. 30, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL) said today that it would like to clarify information about the Company and acknowledge the investor community’s request for comments following Q2 financials. Key facts from the Q2 financials many of which were found in the footnotes: The … Continue Reading

BioElectronics Files FDA 510(k) Application for Musculoskeletal Pain Complaints; Clinical Data Demonstrates Superior Drug Free Pain Relief to Prescription Strength NSAID Drug

FREDERICK, MD, Aug. 20, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com, is pleased to announce that it has filed a 510(k), Premarket Notification application with the U.S. Food and Drug Administration (FDA). The application is to seek expanded market clearance for the drug free, over-the-counter ActiPatch® Musculoskeletal Pain Therapy medical … Continue Reading

BioElectronics Announces FDA Market Clearance for Its Non-Opioid Postoperative Pain Therapy

FREDERICK, MD, July 01, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com, the maker of non-invasive electroceutical devices, is pleased to announce that it has received market clearance from the United States Food and Drug Administration (US FDA) for its RecoveryRx® medical device, for the treatment of postoperative pain. Physicians are … Continue Reading

BioElectronics Announces Publication of Study Verifying the Effectiveness of Its ActiPatch Medical Device on Chronic Pain

FREDERICK, MD, June 03, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC PINK: BIEL) www.bielcorp.com, the maker of non-invasive electroceutical devices, is pleased to announce the publication of a registry study in the May 2019 edition of the Journal of Pain Management. Titled “Chronic pain intervention using pulsed shortwave therapy: the relationship between … Continue Reading

BioElectronics Responds to FDA’s 510(k) Additional Information Requests for its Musculoskeletal Pain Relief and Postoperative Pain Applications

FREDERICK, MD, April 23, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com announced that the Company has submitted its response to the U.S. Food and Drug Administration’s (FDA) request for additional information on its ActiPatch® 510(k) market clearance application for “treatment of musculoskeletal pain in women”. Additionally, the Company has … Continue Reading

Northwest Specialty Hospital Now Offering Electroceutical Alternative To Opioids In Clinical Practice

PR Newswire POST FALLS, Idaho, March 14, 2019 POST FALLS, Idaho, March 14, 2019 /PRNewswire/ — Northwest Specialty Hospital is proud to announce that they are offering electroceutical devices as an alternative to opioid medication for pain management in conjunction with RiversEdge Orthopedics, Axis Spine and Bioelectronics Corporation (OTC PINK: BIEL). According to the National Institute on Drug Abuse, … Continue Reading

BioElectronics Announces Back Pain Clinical Study with Leading Australian Pain Center

Pulsed Shortwave Neuromodulation Therapy (ActiPatch®) Study in Chronic Lower Back Pain FREDERICK, MD, March 08, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC PINK: BIEL) http://www.bielcorp.comis pleased to announce the commencement of a clinical study investigating the efficacy of ActiPatch in treating chronic lower back pain. The objectives of this additional back pain study are … Continue Reading

BioElectronics Files FDA Applications for Treatment of Musculoskeletal & Postoperative Pain

FREDERICK, MD, Feb. 12, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that two Traditional 510(k) Premarket Notification applications were filed with the U.S. Food and Drug Administration (FDA). The applications were for the ActiPatch® and RecoveryRx® medical devices for market clearances of “over-the-counter adjunctive treatment of musculoskeletal … Continue Reading

President’s Response to Stock Price Decline

Frederick, Maryland, Dec. 04, 2018 (GLOBE NEWSWIRE) – Dear Fellow Shareholders: While we were all disappointed by the dramatic drop in the stock price, it hasn’t had an impact on the Company’s operations. What is still needed is a cost-effective efficacious painkiller that is also an alternative to opioids. Physicians prescribe, and patients take opioids … Continue Reading